REVI Opinions 08/17/2014 04:21:34 $REVI Q2s 2014

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
REVI Opinions 08/17/2014 04:21:34 $REVI
Q2s 2014

www.otcmarkets.com/financialReportViewer?symbol=REVI&id=124952

REVI
When we here directly from the company swing up is imminent.
Just loving this.. GO REVI!!
good luck to you!!!
be a team player and slap that ask!!..regardless you'll come out on top!!
REVI
Exactly and i'm looking to catch another 500k shares.

Long and strong is the way to work REVI
i never took you for being a rookie!!!
like the ol Beach Boys said...
let's get together and Do IT Again!!!
REVI
that's what makes us so special...
everybody knows it's a diamond in the rough!
REVI
Amen to that sister.

I'm a witness to the last run. Long, and sells set high!

REVI
minimum of 100%,and that's low balling it.
half a mill shares for 6k can turn into 24k in the MIDDLE of the upcoming run!
REVI
How about that a real company with real financials and way undervalued.

REVI

any body that was lucky enough
to pick up 7's already has 70% gain...not bad!
REVI
You want to get in under .02 you'll have a lot green in front of you.

REVI
REVI BooomB!
REVI should be followed soon by some quarterly news too with solid ass earnings!

READY!
and will be again!!!!
a good friend once told me..flips pay the bills,but long strong big profits bring wealth...the name escapes me now. but God love him...he's right!
REVI
Bouncing around cooking dinner.


REVI
without a doubt!!
hemp magazine first run was in the 3rd qtr!not even in the latest financials!
REVI
took you a while to catch
your breath on that one...ok that'll work
REVI
Heck of a run and it was. Patience here was key

REVI
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 43

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 37

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 47

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 34

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 44

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 38

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing the P/E Ratio of Western Alliance: Insights and Trends

Updated Category News Views 123

Understanding the P/E Ratio of Western Alliance In the current market climate, Western Alliance Inc. (WAL) has seen its share price hit $79.17, reflecting a modest increase of 0.47%. Over the past month, however, the stock has experienced a decrease of 6.61%. Interestingly, despite this recent dip, when we look at the yearly perspective, the stock has climbed by 6.77%...

Continue Reading
Hesai Group Innovates Lidar Technology for Cadillac SUVs

Updated Category News Views 219

Hesai Group Powers Cadillac's VISTIQ with Advanced Lidar Technology Hesai Group, a prominent player in lidar technology, has achieved a significant milestone by partnering with SAIC-GM to integrate its advanced AT series lidar system into Cadillac's new all-electric VISTIQ SUV. This integration represents a breakthrough in automotive design and technology, as it is the...

Continue Reading
Jeffersonville Bancorp Reports Strong Q2 Earnings and Dividend

Updated Category News Views 121

Jeffersonville Bancorp Delivers Impressive Earnings for Q2 Jeffersonville Bancorp, Inc. (OTCQB - JFBC) reported robust second quarter results, showcasing a net income of $3,290,000, equivalent to $0.78 per share. This financial performance indicates a notable increase from the previous year's earnings of $3,031,000, or $0.72 per share, reflecting a significant rise in...

Continue Reading
SAS, NPower Team Up: Disrupting Tech Career Access

Updated Category News Views 12

An Unlikely Alliance Fueling Tech Careers Not every day do you see a big-name data firm strut their stuff in the nonprofit world. SAS has teamed up with NPower to flip the script on tech career access. This isn't just a side project—it's a full-throttle mission to drive hardcore data understanding into communities that have long been left hanging. Right here in Cary,...

Continue Reading
America's Emotional Landscape: Loneliness and Division Exposed

Updated Category News Views 216

Understanding the Impact of Societal Division on Emotional Health Most U.S. adults report feeling isolated, in need of more emotional support Loneliness and a sense of emotional disconnection are increasingly shaping the lifes of individuals in America. Recent findings reveal that a significant majority of U.S. adults feel stressed due to societal division. This insight...

Continue Reading